Idronoxil Confirmed as New Immuno-Oncology Drug
Filed with ASX · · 2 pages · English
Story so far
Earlier from Noxopharm
- Veyonda Chemotherapy Enhancement Program to be Expanded
- KZA: Kazia sells stake in Noxopharm
- Noxopharm to expedite Veyonda Clinical Program
- FNN interview with Nox Chief Medical Officer on Interim Data
- Veyonda and Radiotherapy Delivers Clinical Benefits
Later from Noxopharm
- Veyonda and Immuno-Oncology Effect Explained
- DARRT Treatment Has Lasting Disease Control at Six Months
- LuPIN Trial Demonstrates High Rates of Response
- Promising Data Leads to Expansion of LuPIN Trial
- Conference Hears of Positive Interim Data from LuPIN Trial
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm